News Dr. Lal PathLabs Limited

Equities

LALPATHLAB

INE600L01024

Healthcare Facilities & Services

Market Closed - NSE India S.E. Other stock markets 06:49:45 2025-12-05 am EST			5-day change	1st Jan Change
3,029.60 ^INR	-0.80%		-0.73%	+0.97%

Nov. 26	Dr. Lal PathLabs Opens Complement Testing Lab in India	MT
Nov. 25	Dr. Lal PathLabs Announces the Launch of India's First Dedicated Complement Testing Laboratory	CI

Dr. Lal PathLabs Opens Complement Testing Lab in India	Nov. 26	MT
Dr. Lal PathLabs Announces the Launch of India's First Dedicated Complement Testing Laboratory	Nov. 25	CI
Nomura Adjusts Dr. Lal PathLabs' Price Target to INR4,000 From INR3,870, Keeps at Buy	Nov. 03	MT
Dr. Lal PathLabs Limited, Q2 2026 Earnings Call, Oct 31, 2025	Oct. 31
Dr. Lal PathLabs' Fiscal Q2 Profit Rises; Declares Second Interim Dividend	Oct. 31	MT
Dr. Lal Pathlabs Limited Declares Second Interim Dividend for the Financial Year 2025-26	Oct. 31	CI
Lal Pathlabs to consider issuance of Bonus Shares	Oct. 24	RE
Dr. Lal PathLabs Announces First Laboratory in the Country to Adopt Deep Learning-Based AI Module to Detect Lymph Node Metastasis, Including Micrometastasis, in Cancer Cases	Aug. 20	CI
Nomura Adjusts Dr. Lal PathLabs' Price Target to INR3,870 From INR3,560, Keeps at Buy	Aug. 04	MT
Dr. Lal PathLabs Limited, Q1 2026 Earnings Call, Jul 31, 2025	Jul. 31
Dr. Lal PathLabs Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	Jul. 31	CI
Dr. Lal PathLabs Consolidated Profit Grows in Fiscal Q1	Jul. 31	MT
Dr. Lal Pathlabs Limited Declares Interim Dividend for the Financial Year 2025-26	Jul. 31	CI
Dr. Lal PathLabs Expands Genomics Capabilities with New Sequencing System	Jun. 25	MT
Nomura Adjusts Dr. Lal PathLabs' Price Target to INR3,560 From INR3,315, Keeps at Buy	Apr. 28	MT
Dr. Lal PathLabs Records Growth in Fiscal Q4 Consolidated Profit	Apr. 28	MT
Dr. Lal PathLabs Limited, Q4 2025 Earnings Call, Apr 25, 2025	Apr. 25
India's Dr Lal Path Labs beats quarterly profit view on medical testing boom	Apr. 25	RE
Dr. Lal Pathlabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025, Payable on or Before July 27, 2025	Apr. 25	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Full Year Ended March 31, 2025	Apr. 25	CI
Dr. Lal PathLabs Launches South Asia's First Test for Amyloid Protein Typing	Apr. 15	MT
Dr. Lal Pathlabs Launches Advanced Test For Amyloidosis	Apr. 15	RE
Dr. Lal Pathlabs Limited Launches Advanced Test for Amyloidosis	Apr. 15	CI
Dr. Lal PathLabs Arm Gets Members' Nod for Voluntary Liquidation	Feb. 06	MT
Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR3,315 From INR3,310	Jan. 31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Dr. Lal PathLabs Limited

Equities

LALPATHLAB

INE600L01024

Healthcare Facilities & Services

Filters